Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Charles J. Casamento

Charles J. Casamento is recorded as Board Member at GT Biopharma, Inc. (GTBP), Board Member at Eton Pharmaceuticals, Inc. (ETON) and Chairman and Board Member at Relmada Therapeutics, Inc. (RLMD). GridAI Technologies Corp. reported in an 8-K filed August 7, 2024 that Charles J. Casamento resigned as member of the Board of the Company, effective August 2, 2024. Relmada Therapeutics, Inc. reported in an 8-K filed May 25, 2023 that Charles J. Casamento was appointed Class II Director, effective May 25, 2023. GT Biopharma, Inc. reported in an 8-K filed May 4, 2023 that Charles J. Casamento was appointed member of the Board of Directors, effective May 1, 2023.

“On August 2, 2024, Charles J. Casamento and Terry Coelho resigned as members of the Board of the Company, effective immediately.”
GridAI Technologies Corp. Form 8-K, filed August 7, 2024 · Read the filing
“Stockholders elected the following nominees as directors to hold office until the 2026 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified.”
Relmada Therapeutics, Inc. Form 8-K, filed May 25, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Eton Pharmaceuticals, Inc.

Other people whose current roles at this company are on record from its filings.

Leadership on record at GT Biopharma, Inc.

Other people whose current roles at this company are on record from its filings.

Leadership on record at Relmada Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.